RT Journal Article SR Electronic T1 Metastatic Merkel Cell Carcinoma responding favourably to targeted therapy with 177Lu-DOTATATE: will PRRT evolve as an important treatment approach in Receptor positive cases? JF Journal of Nuclear Medicine Technology JO J. Nucl. Med. Technol. FD Society of Nuclear Medicine SP jnmt.115.163527 DO 10.2967/jnmt.115.163527 A1 BASU, SANDIP A1 Ranade, Rohit YR 2015 UL http://tech.snmjournals.org/content/early/2015/10/14/jnmt.115.163527.abstract AB Excellent partial response with a single cycle of peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE in Merkel cell carcinoma with multiple bilobar hepatic metastases is illustrated in this report. Documentation of such response coupled with minimal side effects would warrant consideration of this therapy early in the disease course, if the metastatic lesions demonstrate adequate tracer avidity on Somatostatin receptor (SSTR) based imaging (rather than in an advanced state following failure of other therapies). Our patient demonstrated systemic disease progression following the second surgery and adjuvant radiotherapy to head and neck and chemotherapy and hence was considered for PRRT. The metastatic lesions demonstrated both SSTR and FDG avidity in the pre-treatment diagnostic study. Scan evidence of partial response in both scan parameters at 3 months before being worked up for the 2nd cycle of PRRT including two lesions demonstrated near-complete resolution. In view of the relative well tolerability, minimal side-effects and targeted nature of the treatment, PRRT can evolve as the first line therapy in patients of metastatic Merkel Cell carcinoma and needs further examination in more patients in the future.